Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death

Loading news article.

Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death | WAPE

Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death

Article summary

Related companies

Comments —